Patricia Huezo-Diaz Curtis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/932907/publications.pdf

Version: 2024-02-01

471371 477173 1,334 29 17 29 citations h-index g-index papers 30 30 30 2039 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Association study of candidate DNA-repair gene variants and acute graft versus host disease in pediatric patients receiving allogeneic hematopoietic stem-cell transplantation. Pharmacogenomics Journal, 2022, 22, 9-18.	0.9	1
2	The analysis of GSTA1 promoter genetic and functional diversity of human populations. Scientific Reports, 2021, 11, 5038.	1.6	9
3	Genetic Susceptibility to Hepatic Sinusoidal Obstruction Syndrome in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 920-927.	2.0	11
4	Incorporation of <i>GSTA1</i> genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation. British Journal of Clinical Pharmacology, 2018, 84, 1494-1504.	1.1	25
5	Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation. Pharmacogenomics Journal, 2018, 18, 64-69.	0.9	13
6	Development and validation of an allele-specific PCR assay for genotyping a promoter and exonic single nucleotide polymorphisms of MGMT gene. Journal of Biological Methods, 2018, 5, e92.	1.0	2
7	GSTA1 Genetic Variants and Conditioning Regimen: Missing Key Factors in Dosing Guidelines of Busulfan in Pediatric Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1918-1924.	2.0	16
8	The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Pharmacology, 2017, 8, 451.	1.6	8
9	GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study. Oncotarget, 2017, 8, 90852-90867.	0.8	39
10	Pharmacogenomics in Pediatric Oncology: Review of Geneâ€"Drug Associations for Clinical Use. International Journal of Molecular Sciences, 2016, 17, 1502.	1.8	27
11	Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients. Bone Marrow Transplantation, 2016, 51, 377-383.	1.3	27
12	Treatment of an Acute Promyelocytic Leukemia Relapse Using Arsenic Trioxide and All-Trans-Retinoic in a 6-Year-Old Child. Pediatric Hematology and Oncology, 2014, 31, 143-148.	0.3	8
13	Personalizing busulfan therapy for children undergoing hematopoietic stem cell transplantation. Personalized Medicine, 2014, 11, 463-466.	0.8	O
14	Pharmacogenetic Aspects of Drug Metabolizing Enzymes in Busulfan Based Conditioning Prior to Allogenic Hematopoietic Stem Cell Transplantation in Children. Current Drug Metabolism, 2014, 15, 251-264.	0.7	34
15	Validation of SYBR Green based quantification assay for the detection of human Torque Teno virus titers from plasma. Virology Journal, 2013, 10, 191.	1.4	20
16	<i>CYP2C19</i> genotype predicts steady state escitalopram concentration in GENDEP. Journal of Psychopharmacology, 2012, 26, 398-407.	2.0	69
17	Ecstasy (MDMA)-induced hyponatraemia is associated with genetic variants in <i>CYP2D6</i> and <i>COMT</i> . Journal of Psychopharmacology, 2012, 26, 408-418.	2.0	17
18	Meta-analyses of genome-wide linkage scans of anxiety-related phenotypes. European Journal of Human Genetics, 2012, 20, 1078-1084.	1.4	28

#	Article	IF	CITATIONS
19	Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project. Pharmacogenomics Journal, 2011, 11, 138-145.	0.9	70
20	No association between genetic markers inBDNFgene and lithium prophylaxis in a Greek sample. International Journal of Psychiatry in Clinical Practice, 2010, 14, 154-157.	1.2	7
21	Moderation of antidepressant response by the serotonin transporter gene. British Journal of Psychiatry, 2009, 195, 30-38.	1.7	143
22	Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-α and ribavirin treatment. Molecular Psychiatry, 2009, 14, 1095-1104.	4.1	214
23	Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics Journal, 2009, 9, 225-233.	0.9	188
24	Genetic Predictors of Increase in Suicidal Ideation During Antidepressant Treatment in the GENDEP Project. Neuropsychopharmacology, 2009, 34, 2517-2528.	2.8	105
25	Association analysis of monoamine genes with measures of depression and anxiety in a selected community sample of siblings. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 135B, 33-37.	1.1	26
26	Genome-wide linkage analysis of a composite index of neuroticism and mood-related scales in extreme selected sibships. Human Molecular Genetics, 2004, 13, 2173-2182.	1.4	107
27	An association study of the neurotensin receptor gene with schizophrenia and clozapine response. Schizophrenia Research, 2004, 66, 193-195.	1.1	13
28	Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response. Schizophrenia Research, 2002, 58, 93-97.	1.1	50
29	The awakening cortisol response and blood glucose levels. Life Sciences, 1999, 64, 931-937.	2.0	51